本帖最后由 sunsong7 于 2010-12-11 19:23 编辑 % P7 E1 s# ^* ` P7 m! ]% [; z5 P" ?, i子曰：“上善若水，大成若缺，干细胞治疗终极解决方案是不使用外源干细胞。”; ~2 C( v8 U# W% ^1 t
这篇文章非常值得一读。 . W; F$ o3 l0 v4 Y$ _ ! v6 v- Y- Q( G E2 ~* s, L摘译这篇文章摘要： & M2 {0 N3 R/ _, o% t 过去几年在骨髓源性干细胞(BMSC)治疗的深入的研究促进了其医学转化。虽然许多已经完成,大量的挑战仍在前面。此外,越来越多的证据表明输注BMSC培养液（BMSC-CM）可以增强干细胞治疗后症状改善作用。BMSCs生产各式各样的因子和趋化因子并显示广泛的医疗潜力。这些旁分泌机制可以用于刺激受体-介导生存通路、诱导干细胞归巢和分化列、调节创伤部位的抗炎效应等多种作用。本文反射出为了缓解在细胞治疗过程中许许多多传运和技术问题的挑战，人们将兴趣由BMSC向BMSC-CM迅速转移,从而显示它在未来的未来再生医学中的潜在作用。 ! A, j9 [( O3 m During the past several years, there has been intense research in the field of bone marrow-derived stem cell (BMSC) therapy to facilitate its translation into clinical setting. Although a lot has been accomplished, plenty of challenges lie ahead. Furthermore, there is a growing body of evidence showing that administration of BMSC-derived conditioned media (BMSC-CM) can recapitulate the beneficial effects observed after stem cell therapy. BMSCs produce a wide range of cytokines and chemokines that have, until now, shown extensive therapeutic potential. These paracrine mechanisms could be as diverse as stimulating receptor-mediated survival pathways, inducing stem cell homing and differentiation or regulating the anti-inflammatory effects in wounded areas. The current review reflects the rapid shift of interest from BMSC to BMSC-CM to alleviate many logistical and technical issues regarding cell therapy and evaluates its future potential as an effective regenerative therapy.; f/ ~. S: c$ o- h
" B. `2 E- h5 ~, W- ^4 Y. e, a5 Z 作者: 橙味绿茶 时间: 2015-5-28 13:27